Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial

被引:48
|
作者
Gault, Emma Jane [1 ]
Perry, Rebecca J. [1 ]
Cole, Tim J. [2 ]
Casey, Sarah [3 ]
Paterson, Wendy F. [1 ]
Hindmarsh, Peter C. [4 ]
Betts, Peter [5 ]
Dunger, David B. [6 ]
Donaldson, Malcolm D. C. [1 ]
机构
[1] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland
[2] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England
[3] Royal Hosp Sick Children, Dept Clin Trials, Dept Pharm, Glasgow G3 8SJ, Lanark, Scotland
[4] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England
[5] Southampton Univ Hosp NHS Trust, Dept Paediat, Southampton, Hants, England
[6] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2011年 / 342卷
关键词
GROWTH-HORMONE TREATMENT; ESTROGEN REPLACEMENT; GIRLS; THERAPY; MULTICENTER; NORMALIZATION; MANAGEMENT; STATURE; AGE;
D O I
10.1136/bmj.d1980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Design Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. Participants Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week). Interventions Participants were randomised to oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of ovarian failure at 12 years were further randomised to oral ethinylestradiol (year 1, 2 mu g daily; year 2, 4 mu g daily; year 3, 4 months each of 6, 8, and 10 mu g daily) or placebo; participants who received placebo and those recruited after the age of 12.25 years started ethinylestradiol at age 14. Main outcome measure Final height. Results 106 participants were recruited, of whom 14 withdrew and 82/92 reached final height. Both oxandrolone and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm (P=0.05, n=48) for late pubertal induction with ethinylestradiol. In the 48 children who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of oxandrolone alone, late induction alone, and oxandrolone plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No cases of virilisation were reported. Conclusion Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Randomised, Double Blind, Placebo-Controlled Trial of Echinacea Supplementation in Air Travellers
    Tiralongo, E.
    Lea, R. A.
    Wee, S. S.
    Hanna, M. M.
    Griffiths, L. R.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012
  • [42] A randomised, double-blind, placebo-controlled trial of a Bach Flower Remedy
    Armstrong, NC
    Ernst, E
    PERFUSION, 1999, 12 (11): : 440 - 446
  • [43] Assessment of the Probiotic Symprove in Patients With IBS: A Randomised Double Blind Placebo Controlled Trial
    Sisson, Guy
    Ayis, Salma
    Bjarnason, Ingvar T.
    GASTROENTEROLOGY, 2012, 142 (05) : S815 - S815
  • [44] Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial
    Ludvigsson, J
    Samuelsson, U
    Ernerudh, J
    Johansson, C
    Stenhammar, L
    Berlin, G
    ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 85 (02) : 149 - 154
  • [45] ASSESSMENT OF THE PROBIOTIC SYMPROVE IN PATIENTS WITH IBS: A RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL
    Bjarnason, I.
    Sisson, G.
    Ayis, S.
    GUT, 2012, 61 : A104 - A104
  • [46] A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED TRIAL OF LITHIUM CARBONATE FOR THE MANAGEMENT OF CANNABIS WITHDRAWAL
    Johnston, Jennifer
    Lintzeris, Nicholas
    McGregor, Iain
    Allsop, David J.
    Helliwell, David
    Winstock, Adam
    DRUG AND ALCOHOL REVIEW, 2013, 32 : 43 - 43
  • [47] Paracervical anaesthesia in outpatient hysteroscopy: a randomised double-blind placebo controlled trial
    Hitchings, S
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2000, 107 (01): : 143 - 144
  • [48] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
    Athauda, Dilan
    Maclagan, Kate
    Skene, Simon S.
    Bajwa-Joseph, Martha
    Letchford, Dawn
    Chowdhury, Kashfia
    Hibbert, Steve
    Budnik, Natalia
    Zampedri, Luca
    Dickson, John
    Li, Yazhou
    Aviles-Olmos, Iciar
    Warner, Thomas T.
    Limousin, Patricia
    Lees, Andrew J.
    Greig, Nigel H.
    Tebbs, Susan
    Foltynie, Thomas
    LANCET, 2017, 390 (10103): : 1664 - 1675
  • [49] Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma
    Shaheen, Seif O.
    Newson, Roger B.
    Rayman, Margaret P.
    Wong, Angela P-L
    Tumilty, Michael K.
    Phillips, Joanna M.
    Potts, James F.
    Kelly, Frank J.
    White, Patrick T.
    Burney, Peter G. J.
    THORAX, 2007, 62 (06) : 483 - 490
  • [50] Sublingual immunotherapy for Alternaria. Randomised, double-blind, placebo controlled trial
    Cortellini, G.
    Santucci, A.
    Corvetta, A.
    Patella, V
    Fabbri, E.
    Spadolini, I
    Severino, M.
    Passalacqua, G.
    ALLERGY, 2010, 65 : 172 - 173